主要文件

查看所有文档

CDS022173

伊马替尼

Name: 伊马替尼
Brand: ALDRICH

别名:

4-(4-甲基哌嗪-1-甲基)-N-[4-甲基-3-[[4-(吡啶-3-基)嘧啶-2-基]氨基]苯基]苯甲酰胺, 4-[(4-甲基-1-哌嗪)甲基]-N-[4-甲基-3-[[4-(3-吡啶)-2-嘧啶]氨基]苯基]苯甲酰胺, CGP 57148, N-(4-甲基-3-((4-(吡啶-3-基)嘧啶-2-基)氨基)苯基)-4-((4-甲基哌嗪-1-基)甲基)苯甲酰胺, 甲磺酸伊马替尼

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₂₉H₃₁N₇O

化学文摘社编号:

152459-95-5

分子量:

493.60

UNSPSC Code:

12352200

PubChem Substance ID:

329795436

MDL number:

MFCD05662257

NACRES:

NA.21

Form:

solid

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

description

Aldrich^CPR

form

solid

SMILES string

O=C(C(C=C1)=CC=C1CN2CCN(C)CC2)NC3=CC(NC4=NC(C5=CN=CC=C5)=CC=N4)=C(C)C=C3

InChI

1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)

InChI key

KTUFNOKKBVMGRW-UHFFFAOYSA-N

Gene Information

human ... ABL1(25), KIT(3815), PDGFRB(5159)

说明

General description

伊马替尼(Imatinib)是一种苯甲酰胺衍生物，用作特定酪氨酸激酶受体抑制剂。可抑制费城(Philadelphia, Ph)染色体异常导致的断裂点簇集区(BCR)-Abelson(ABL)融合蛋白。伊马替尼也用作强效的凋亡诱导剂和抗肿瘤药。

Other Notes

请注意，Sigma-Aldrich将本品作为一系列特殊化学品的一部分提供给早期发现研究人员。Sigma-Aldrich不收集本品的分析数据。买方承担确认产品特性和/或纯度的责任。所有销售均为最终销售。

尽管SIGMA-ALDRICH的标准条款和条件以及SIGMA-ALDRICH和买方之间的协议中包含所有合同条款，但无论是在法律、交易过程、执行过程中的行为、以及贸易或其他方面的使用等过程中，SIGMA-ALDRICH按“原样”销售此产品并且并对此产品不作任何陈述或担保，包括：(A)适销性担保；(B)特定用途适用性担保；或(C)未侵犯第三方知识产权担保。

pictograms

GHS08

signalword

Danger

hcodes

H341,H351,H360D,H362

pcodes

P202 - P260 - P263 - P264 - P280 - P308 + P313

Hazard Classifications

Carc. 2 - Lact. - Muta. 2 - Repr. 1B

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Upregulation of miR-99a is associated with poor prognosis of acute myeloid leukemia and promotes myeloid leukemia cell expansion.

Xiaohui Si et al.

Oncotarget, 7(47), 78095-78109 (2016-11-02)

Leukemia stem cells (LSCs) can resist available treatments that results in disease progression and/or relapse. To dissect the microRNA (miRNA) expression signature of relapse in acute myeloid leukemia (AML), miRNA array analysis was performed using enriched LSCs from paired bone

Molecular Mobility and Stability Studies of Amorphous Imatinib Mesylate.

Bożena Karolewicz et al.

Pharmaceutics, 11(7) (2019-07-04)

The proposed study examined the characterization and stability of solid-state amorphous imatinib mesylate (IM) after 15 months under controlled relative humidity (60 ± 5%) and temperature (25 ± 2 °C) conditions. After 2 weeks, and 1, 3, 6, and 15

Hydroxychavicol sensitizes imatinib-resistant chronic myelogenous leukemia cells to TRAIL-induced apoptosis by ROS-mediated IAP downregulation.

Tamalika Paul et al.

Anti-cancer drugs, 30(2), 167-178 (2018-11-13)

The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a member of cytokine superfamily, induces apoptosis in a number of tumor cells through the activation of extrinsic apoptotic pathway but shows little or no cytotoxicity toward normal cells. However some tumor cells

查看所有相关文献

全球贸易项目编号

货号	GTIN
CDS022173-25MG	04061828999897